scispace - formally typeset
W

Wolf-Dietrich Doecke

Researcher at Bayer HealthCare Pharmaceuticals

Publications -  9
Citations -  1293

Wolf-Dietrich Doecke is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Interleukin 20 & Transactivation. The author has an hindex of 6, co-authored 9 publications receiving 1214 citations. Previous affiliations of Wolf-Dietrich Doecke include Schering AG & Charité.

Papers
More filters
Journal ArticleDOI

Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study.

TL;DR: Hydrocortisone therapy restored hemodynamic stability and differentially modulated the immunologic response to stress in a way of antiinflammation rather than immunosuppression.
Journal ArticleDOI

IL-22 Induces Lipopolysaccharide-Binding Protein in Hepatocytes: A Potential Systemic Role of IL-22 in Crohn’s Disease

TL;DR: It is demonstrated that IL-22, a cytokine that is mainly produced by activated Th1 and Th17 cells, was present in high quantities in the blood of CD patients in contrast to IFN-γ and IL-17 and found an up-regulation of LPS-binding protein (LBP) blood levels reaching concentrations known to neutralize LPS.
Journal ArticleDOI

Interleukin (IL)‐19, IL‐20 and IL‐24 are produced by and act on keratinocytes and are distinct from classical ILs

TL;DR: The notion that IL‐19, IL‐20 and IL‐24 are distinct from classical ILs and constitute a separate subfamily of mediators within the IL‐10 family is supported.
Journal ArticleDOI

IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis

TL;DR: It is demonstrated that out of 30 individually quantified cytokines, IL-19 showed the strongest differential expression between psoriatic lesions and healthy skin and might be a biomarker for the activity of this axis in chronic inflammatory disorders.
Journal ArticleDOI

Standardized immune monitoring for the prediction of infections after cardiopulmonary bypass surgery in risk patients.

TL;DR: The diagnostic value of a standardized immune monitoring program based on recent advances in flow cytometry (exact quantification of surface‐marker expression) and cytokine determination (semiautomatic systems) is studied.